We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
Read MoreHide Full Article
Alexion Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation (ODD) to ALXN1210, a longer-acting anti-C5 antibody that inhibits terminal complement, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare, life-threatening blood disorder.
Shares of Alexion have outperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year. Specifically, the stock has lost 11.1% in the past one year, while the industry witnessed a decline of 12.7%.
We note that the FDA, through its Office of Orphan Products Development, usually grants ODD to those drugs and biologics that are being developed for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders affecting less than 200,000 people in the U.S. On receiving the status, the company developing it is entitled to certain benefits and incentives, including a period of marketing exclusivity upon regulatory approval for the designated indication.
Alexion is currently evaluating ALXN1210 in phase III studies for PNH as well as for atypical hemolytic uremic syndrome (aHUS), another ultra-rare and life-threatening disease. Additionally, the company is conducting a phase I study on a new formulation of ALXN1210 when administered subcutaneously in healthy volunteers.
Meanwhile, Alexion has completed enrollment in two ongoing studies on ALXN1210 in patients with PNH – a phase I/II dose-escalating study and an open-label, multi-dose phase II study on longer dosing intervals beyond 8 weeks.
We are encouraged by the FDA granting ODD to ALXN1210. The candidate also received ODD in the EU last June for the treatment of PNH.
We note that Alexion’s key growth driver, Soliris, is approved for the treatment of both PNH and aHUS. The company is also developing Soliris for additional indications including refractory generalized myasthenia gravis and neuromyelitis optica spectrum disorder.
Alexion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this industry include Arbutus Biopharma Corporation (ABUS - Free Report) , Epizyme, Inc. and Orexigen Therapeutics, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arbutus’ loss estimates narrowed 2.8% and 0.7% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Epizyme’s loss estimates narrowed 3% and 2.4% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise in each of the four trailing quarters, with an average beat of 14.03%. Its share price gained approximately 13% in the past one year.
Orexigen’s loss estimates for 2016 and 2017 have narrowed 8.5% and 52.4%, respectively, over the last 60 days.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
Alexion Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation (ODD) to ALXN1210, a longer-acting anti-C5 antibody that inhibits terminal complement, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare, life-threatening blood disorder.
Shares of Alexion have outperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year. Specifically, the stock has lost 11.1% in the past one year, while the industry witnessed a decline of 12.7%.
We note that the FDA, through its Office of Orphan Products Development, usually grants ODD to those drugs and biologics that are being developed for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders affecting less than 200,000 people in the U.S. On receiving the status, the company developing it is entitled to certain benefits and incentives, including a period of marketing exclusivity upon regulatory approval for the designated indication.
Alexion is currently evaluating ALXN1210 in phase III studies for PNH as well as for atypical hemolytic uremic syndrome (aHUS), another ultra-rare and life-threatening disease. Additionally, the company is conducting a phase I study on a new formulation of ALXN1210 when administered subcutaneously in healthy volunteers.
Meanwhile, Alexion has completed enrollment in two ongoing studies on ALXN1210 in patients with PNH – a phase I/II dose-escalating study and an open-label, multi-dose phase II study on longer dosing intervals beyond 8 weeks.
We are encouraged by the FDA granting ODD to ALXN1210. The candidate also received ODD in the EU last June for the treatment of PNH.
We note that Alexion’s key growth driver, Soliris, is approved for the treatment of both PNH and aHUS. The company is also developing Soliris for additional indications including refractory generalized myasthenia gravis and neuromyelitis optica spectrum disorder.
Alexion Pharmaceuticals, Inc. Price and Consensus
Alexion Pharmaceuticals, Inc. Price and Consensus | Alexion Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Alexion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this industry include Arbutus Biopharma Corporation (ABUS - Free Report) , Epizyme, Inc. and Orexigen Therapeutics, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Arbutus’ loss estimates narrowed 2.8% and 0.7% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Epizyme’s loss estimates narrowed 3% and 2.4% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise in each of the four trailing quarters, with an average beat of 14.03%. Its share price gained approximately 13% in the past one year.
Orexigen’s loss estimates for 2016 and 2017 have narrowed 8.5% and 52.4%, respectively, over the last 60 days.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>